Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)

Ad hoc announcement pursuant to Art. 53 LR Phase III APPEAR-C3G study met its primary endpoint, demonstrating superiority of iptacopan vs. placebo in proteinuria reduction at six-month analysis1;...

Related Keywords

Praga ,Praha ,Hlavníesto ,Czech Republic ,Switzerland ,United States ,America ,Sloan Simpson ,Satoshi Sugimoto ,Parag Mahanti ,Isabella Zinck ,Jonathan Graham ,Julie Masow ,Samir Shah ,Richard Jarvis ,Shreeram Aradhye ,Zain Iqbal ,Nicole Zinsli Somm ,Imke Kappes ,Marlena Abdinoor ,Michael Meo ,Facebook ,Glomerular Diseases Work Group ,National Kidney Foundation ,Exchange Commission ,European Medicines Agency ,Novartis Pharmaceuticals ,Novartis Pharmaceuticals Corp ,Instagram ,Novartis ,University Of Washington ,Linkedin ,Chief Medical Officer ,Therapy Designation ,Accessed December ,Kidney Int ,Narrative Review ,Rare Renal ,Intj Mol ,Dense Deposit ,Rare Complement Driven Renal ,Nat Rev ,Hemolytic Uremic Syndrome ,Improving Global ,Improving Global Outcomes ,Glomerular Diseases Work ,Practice Guideline ,Primary Iga Nephropathy Patients ,Complement Inhibitor Therapy ,Participants With ,Complement Pathway Inhibition With Iptacopan ,Study Design ,East Hanover ,Clinicopathologic Features ,Clinj Am Soc ,Genetic Complement Abnormalities Play ,Critical Role ,Dense Deposit Disease ,Immune Complex ,Nephrol Dial ,Rare Pediatric Disease Designation ,Global Facts ,About Kidney ,Markets ,